New insights into checkpoint inhibitor immunotherapy and its combined therapies in hepatocellular carcinoma: from mechanisms to clinical trials

Haoer Jin¹, Sha Qin¹, Jiang He², Juxiong Xiao³, Qingling Li¹, Yitao Mao³,⁴*, Luqing Zhao¹,⁴*

¹Department of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan, China; and Department of Pathology, School of Basic Medical Science, Xiangya School of Medicine, Central South University, Changsha, Hunan, China.

²Center for Molecular Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, China.

³Department of Radiology, Xiangya Hospital, Central South University, Changsha, Hunan, China.

⁴National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China.

*To whom correspondence should be addressed:

Dr. Luqing Zhao, Department of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan, China, E-mail: luqingzhao@csu.edu.cn.

Or Dr. Yitao Mao, Department of Radiology, Xiangya Hospital, Central South University, Changsha, Hunan, China, E-mail: maoyt@csu.edu.cn.
Abstract

Hepatocellular carcinoma (HCC) is one of the most lethal tumors in China and worldwide, although first-line therapies for HCC, such as atezolizumab and bevacizumab, have been effective with good results, the researches on new therapies have attracted much attention. With the deepening research on tumor immunology, the role and operation mechanism of immune cells in the tumor microenvironment (TME) of HCC have been explained, such as programmed cell death protein 1 (PD-1) binding to ligand could cause T cell exhaustion and reduce IFN-γ T cell secretion, cytotoxic T lymphocyte 4 (CTLA-4) and CD28 mediate immunosuppression by competing for B7 protein and disrupting CD28 signal transduction pathway, which also lays the foundation for the development and application of more new immune checkpoint inhibitors (ICIs). The biological behavior of various immune checkpoints has been proved in HCC, such as PD-1, programmed cell death ligand 1 (PD-L1), CTLA-4 and so on, leading to a series of clinical trials. Currently, FDA approved nivolumab, pembrolizumab and nivolumab plus ipilimumab for the treatment of HCC. However, the treatment of ICI has the disadvantages of low response rate and many side effects, so the combination of ICIs and various other therapies (such as VEGF or VEGFR inhibition, neoadjuvant and adjuvant therapy, locoregional therapies) has been derived. Further studies on immune checkpoint mechanisms may reveal new therapeutic targets and new combination therapies in the future.

Keywords: Hepatocellular carcinoma (HCC), Tumor microenvironment (TME),
1. Background

According to the latest statistics in 2021, HCC was the sixth most commonly diagnosed cancer and the third leading cause of cancer death globally[1]. Compared with other regions, the incidence rate of HCC is highest in East Asia. Among those countries, Mongolia has the highest incidence (93.7 per 100,000)[2]. With the progress of science and medicine, the treatment of HCC has a great development. Treatments of HCC are mainly based on tumor stage. Researchers have put forward many kinds of cancer staging systems, of which Barcelona Clinic HCC (BCLC) staging system is most widely recognized and clinically used[3]. According to the early stage HCC patients, they are primarily treated by surgery, such as hepatic resection (HR), liver transplantation, ablation, etc. For the intermediate-stage HCC patients, transarterial chemoembolization (TACE) is the treatment of choice. Before 2016, there was only sorafenib in the systematic therapy of patients with advanced hepatocellular carcinoma (aHCC). With the deepening of research on the treatment of HCC in recent years, tumor immunotherapy provides a new direction for the treatment[4-8].

Immunotherapy may be a hotspot in the treatment of HCC in the next few years. In this paper, we studied the role of immune cells in the TME of HCC, summarized
the immune checkpoints and their ligands in the field of HCC, concluded the clinical progress of ICIs, and discussed and compared the current use of the combined ICIs strategy. Finally, we review the future development of ICIs in HCC.

2. The immune network in TME of HCC

Immune cells play an important role in TME. Among them, the innate immune system of liver is very necessary in the process of resisting tumor invasion, mainly including natural killer (NK) cells, Kupffer cells (KCs) and dendritic cells (DCs)[9]. In addition, tumor-infiltrating lymphocyte (TIL) is an important component of solid tumors, which is the host's attempt to mediate anti-tumor response[10]. However, more and more experimental data showed that TIL in HCC could not produce effective anti-tumor immunity to inhibit tumor progression[11]. Therefore, immunosuppressive cells play a major role in tumor immune tolerance and immune evasion in HCC, including tumor-associated macrophages (TAMs), regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs) in HCC tumor microenvironment[12-14] (Figure 1).

2.1 Natural killer cell (NK)

NK cells are one of the major lymphocytes in liver immunity, accounting for 30 %-50 % of the total number of lymphocytes in the liver[15]. NK cells can express a variety of cytokines to regulate immune function. In HCC, NK cells are exhausted, but they highly express immune checkpoints and secrete immunosuppressive
cytokines, such as TGFβ, IL-10 and IFN-γ[16, 17]. This involves a general mechanism in liver diseases, referring to MDSC-mediated NK cell impairment. After the NK cells of HCC patients were cultured with M-MDSCs in vitro, the cytotoxicity of NK cells was significantly reduced, and the secretion of IFN-γ was also reduced[18]. Notably, experimental data showed that the frequency of NK cells in peripheral blood and liver were positively correlated with the survival time of patients with HCC[19]. NK cells and CD8+ T cells in tumors have increased T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3) expression[20]. Zhang PF et al found that circUHRF1 was highly expressed in HCC tissue and exosome derived from HCC. Besides, they demonstrated that circUHRF1 could up-regulate the expression of TIM-3 through sponge miR-449c-5p, resulting in NK cell exhaustion. Finally, they concluded that the exocrine circUHRF1 secreted by HCC cells reduces the effectiveness of anti-PD-1 therapy by inducing NK cell exhaustion[21]. Tan, S et al. used flow cytometry to analyze the single cells infiltrated by HCC, and found that NK cells were significantly reduced, while TIM-3 expression was increased. After blocking TIM-3, the depleted NK cells function quickly recovered, thereby inhibiting tumor growth[22]. Taken together, simultaneous use of TIM-3 and/or PD-1 inhibitors can reverse T cell depletion and reduce tumor growth.

2.2 Dendritic cell (DC)

DCs can present antigen, control T cell differentiation and regulate T cell response[23]. DCs initiate T cells against tumor associated antigens (TAA) involved
DCs can promote tumor growth in HCC patients. There are mainly two mechanisms, namely, inducing tolerance to tumor antigens and inhibiting T cell function by releasing cytokines or expression immune checkpoint ligands. HCC cells can induce immature differentiation of DCs by secreting immunosuppressive factors such as IL-10 and VEGF. Immature DCs promote tumor tolerance by inducing CD8\(^+\) Treg and inhibit the function of other effector T cells[24]. In HCC tumor immune microenvironment, DCs promote Tregs and impair T cells proliferation by reducing IL-12 secretion[25]. Based on the characteristics of DCs, researchers had conducted several clinical trials to assess the efficacy of DC vaccines in patients with HCC. For example, in patients with advanced HCC, mature autologous DCs with isolated pulse of liver tumor cell line lysate (HepG2) were injected intravenously, and it was found that HCC patients had good tolerance to the vaccine[26]. However, the overall results of DC vaccination alone have not significantly improved the therapeutic effect. In a recent study, researchers used DC vaccine combined with PD-L1 inhibitor in a mouse model of HCC[27]. Compared with the single treatment, the combined treatment of DC vaccine and PD-L1 inhibitor can induce higher levels of tumor cell apoptosis by increasing the infiltration of cytotoxic T cells against tumor cells.

### 2.3 Kupffer cell (KC) and Tumor-associated macrophage (TAM)

Liver macrophages are composed of KCs and recruited macrophages. KCs are resident groups of liver macrophages, which mainly exist in the hepatic sinusoidal.
KCs account for about 20% of non-solid cells in the liver[28]. During host defense, KCs perceive pathogens and coordinate inflammatory responses, including phagocytosis, antigen processing and presentation, and secretion of proinflammatory mediators[25]. KCs are considered to be HCC-specific TAMs[29].

TAMs in HCC microenvironment are closely associated with poor prognosis. Studies have demonstrated that TAMs repolarization to anti-tumor phenotype promotes tumor regression. In general, macrophages can polarize into M1 or M2 macrophages, and stimulation of factors such as INF-γ can activate M1 polarized macrophages. M1 polarization can produce immune stimulating factors and promote inflammation, such as IL-12 or TNF-α[30]. However, it was found that M2-polarized macrophages were more similar to TAMs, and the former could be activated by Th2 cytokines, namely IL-13 and IL-4[31] (Figure 2). Yang Y et al. first reported that Wnt ligands derived from tumor cells promote polarization of M2 macrophages through canonical Wnt/β-catenin signaling, leading to tumor growth, migration, metastasis and immunosuppression in HCC[32]. More and more researchers have focused on blocking Wnt secretion and/or activating of Wnt/β-catenin signaling in tumor cells. For example, long noncoding RNA LINC00662 was demonstrated to be able to up-regulate the expression of WNT3A by binding to miR-15a/16/107, activate Wnt/β-catenin signaling, and further promote the proliferation and growth of HCC cells in vivo. At the same time, WNT3A induces the polarization of M2 macrophages in a paracrine manner[32-34] (Figure 3).

TAMs can produce a variety of chemokines and interact with other immune cells.
For example, IL-1β released by M2-TAMs can promote EMT and metastasis of HCC cells under hypoxia through HIF-1α/IL-1β/TLR4 axis[35]. CCL22 and CCL17 can recruit Tregs to move to the cancer site, which enhances immune evasion[36]. It has been reported that the inhibitory cytokine IL-10 secreted by Tregs contributes to the M2 polarization of TAMs. In addition, Tregs could promote M2 polarization of TAMs by inhibiting CD8⁺ T cell-IFN-γ axis[37]. This suggests that there may be a positive feedback loop between TAMs and Tregs, providing a new perspective for the immunosuppressive effect of cancer. It was reported that the number of Tregs in HCC patients increased[38], and the proportion and absolute number of Foxp3⁺ CD25⁺ CD4⁺ Treg subsets increased significantly.

2.4 Regulatory T cell (Treg)

Yang Y et al. examined 235 surgical specimens from HCC patients and found that CD8⁺ T cells were exhausted and Tregs were accumulated in tumors. Multiple markers (LAG-3, TIM-3, CTLA-4, PD-1 and other immune checkpoints) co-expressed in T cells of HCC, thus blocking these immune checkpoints may reverse exhausted T cells[39]. Tregs are a kind of CD4⁺ T cells that can be divided into two groups: natural regulatory T cells (nTregs) and induced-to-adjust T cells (iTregs). Both kinds of Tregs express Foxp3[40]. nTregs are present in the thymus, induced by autoantigens and inhibited by intercellular contact. Unlike nTregs, iTregs are originated from peripheral naïve CD4⁺ T cells induced by cytokines specific to the tumor microenvironment, such as IL-10, TGF-β[41]. TGF-β and IL-10 promote the
differentiation of iTregs by up-regulating the expression of Foxp3 and CTLA-4, leading to the proliferation and migration of tumor cells, resulting in poor prognosis of patients[42]. With the progress of tumor, tumor cells secrete TGF-β in an autocrine manner, forming a positive feedback. Although there are differences between nTregs and iTregs, it is difficult to distinguish these two types in vivo, and nTregs and iTregs are rarely distinguished in the literature describing Treg in TME[43].

Tregs can maintain immunosuppressive state in tumor microenvironment by releasing inhibitory cytokines such as transforming growth factor (TGF)-β, IL-10 and IL-35[38, 44]. Tregs can inhibit anti-tumor immunity, DC antigen presentation and CD4+ T helper (Th) cell function. Shi C et al found that Tregs promoted the migration and invasion of Hepa1-6 cells in vitro and in vivo through EMT. In the wound healing experiment, Hepa1-6 cells treated with Tregs-CM had faster healing effect, which was also detected by transwell migration assay. In addition, after using TGF-β1 neutralizing antibody in Treg-CM, the EMT ability and colony formation ability of Hepa1-6 cells were significantly decreased. Therefore, it can be speculated that the consumption of TGF-β1 can block the effect of Tregs-induced EMT, which may be a potential reason for promoting the invasive migration of HCC cells[45]. It is worth noting that IL-10 and IL-35 secreted by Tregs can directly induce the expression of inhibitory receptors on CD8+ cytotoxic T lymphocytes (CTLs) in tumors and promote T cells exhaustion by regulating the BLIMP1 inhibitory receptor axis in CD8+ T CTLs[46].
2.5 Myeloid-derived suppressor cells (MDSC)

MDSC, as a heterogeneous kind of immature myeloid cells, are divided into two major MDSC subsets: mononuclear MDSC (M-MDSC) and polymorphonuclear MDSC (PMN-MDSC)[47]. Both subgroups have been verified to have immunosuppressive effects. PMN-MDSCs are the main components of MDSCs in tumor-bearing mice, and have the same morphology and characteristics as neutrophils. They inhibit antigen-specific CD8⁺ T cells by producing high levels of reactive oxygen species (ROS)[47, 48]. However, in the surrounding tissues of HCC patients, the number of M-MDSCs is more than that of PMN-MDSCs[49]. M-MDSCs have similar morphology and characteristics to monocytes and are considered to have stronger immunosuppressive activity in tumor microenvironment than PMN-MDSCs in some cases[50]. M-MDSCs produce a large number of NO, arginase-1 and immunosuppressive cytokines. Since these molecules have longer half-life period, M-MDSCs can effectively inhibit nonspecific T cell response without the requirement for close contact between M-MDSCs and T cells[51]. Liu M et al. reported that activated hepatic stellate cells (HSC) can activate P38 MAPK signaling in M-MDSCs and then promote the accumulation and function of M-MDSCs through chromatin regulation mediated by CCAAT-Enhancer-Binding Protein Beta (C/EBPβ)[49]. However, Liu M did not point out which cytokines secreted by HSCs caused this phenomenon. Another article expounded that HSCs could secrete IL-6 to promote the proliferation of MDSCs (mainly M-MDSCs), and make MDSCs secrete more immunoregulatory enzymes, such as inducible nitric oxide synthase (iNOS) and arginine 1[52].
In conclusion, MDSCs have two main functions: on the one hand, it promotes tumor progression by inhibiting the anti-tumor function of T cells and NK cells; on the other hand, MDSCs also promote new angiogenesis and tumor cell invasion[53]. Previous studies have shown that MDSCs from HCC patients can inhibit the cytotoxicity and cytokine secretion of NK cells when cultured with NK cells in vitro[54]. MDSCs can express high levels of PD-L1, and can also recruit Tregs by expressing CD40. In addition, MDSCs can also express a variety of immunosuppressive cytokines, such as TGF-β, IL-10[55].

During the development of HCC, immune cells have different effects in different pathways. Focusing on immune cells, researchers have developed a variety of immunomodulators and used them in cancer therapy, leading to a breakthrough in the study of ICIs[56]. ICIs act on T cells, mainly cytotoxic T lymphocytes, and activates downstream immune pathways to achieve anti-tumor purposes. Antibodies aiming at molecular CTLA-4, PD-1, PD-L1 and so on have been used in many kinds of tumors, and therapeutic effects have been achieved[57-60]. Below, we discuss their roles in HCC and focus on their strategies of immunotherapy.

3. Systemic treatment in HCC

3.1 Immune checkpoints in HCC

3.1.1 PD-1 and PD-L1/PD-L2

Under the normal physiological condition, the human immune system protects the host from disease invasion through the cooperation of various immune cells.
However, growing evidences indicate that tumors utilize a variety of methods such as immune checkpoints in the immune system to evade anti-tumor immune response[61, 62] (Figure 4). Only a small number of patients have improved symptoms. Understanding the drug resistance mechanism is necessary to improve the efficacy of anti-PD-1[63]. PD-1, also known as CD279, is an immunosuppressive molecule[64]. In HCC, Binding of PD-1 to ligand triggers downregulation of T cell receptor, inhibits T cell activation and cytokine release. It regulates the immune system and promotes self-tolerance by down-regulating the response of the immune system to human cells and inhibiting the inflammatory activity of T cells. PD-1 is expressed on activated T cells, B cells and macrophages and negatively regulates immune response more widely than CTLA-4[57, 64-67].

The ligands for PD-1 are PD-L1 (also known as B7-H1 or CD274) and PD-L2 (also known as B7-DC or CD273). They belong to the B7 family of type I transmembrane protein receptors. PD-L1 is widely expressed in hematopoietic as well as non-hematopoietic cells[68]. Binding of PD-L1 to PD-1 on T cells leads to dephosphorylation of T cell receptor, resulting in reducing T cell proliferation and activity. Tumor cells make use of this mechanism to escape immune surveillance[69]. Different from PD-L1, PD-L2 was initially thought to be predominantly expressed in APCs, such as DCs, macrophages and bone marrow-derived mast cells. However, recent studies have shown that PD-L2 can be expressed by various immune cells and tumor cells under microenvironment stimulation. Some studies demonstrate that PD-
L2 expression in tumor cells is a predictive factor for the clinical efficacy of anti-PD-L1 mAb[70, 71].

T cell exhaustion could be defined as a state of differentiation observed during chronic infection with persistent antigen and chronic T cell receptor (TCR) stimulation[72, 73]. With the rapid development of oncology, in-depth study of this concept is of great significance for checkpoint blockade. Compared with normal T cells, exhausted T cells consistently express multiple inhibitory receptors, such as PD-L1, TIM-3[74]. When T cells were exhausted seriously, the co-expression of TIM-3 and PD-1 could be observed, suggesting that the clinical prognosis of HCC was poor[75, 76]. Studies have shown that blocking PD-1 inhibitory receptors in vivo can restore depleted T cells by acting on the TME[77].

A recent study found that OTU domain-containing ubiquitin aldehyde-binding protein 1 (OTUB1) regulates the activation of CD8⁺ T cells and NK cells through IL-15[78]. Meanwhile, OTUB1 regulates PD-L1 abundance through the endoplasmic reticulum-associated degradation (ERAD) pathway. Degradation of PD-L1 increased and content decreased due to lack of OTUB1. OTUB1 deficiency leads to HCC cells to become more sensitive to T cell mediated cytotoxicity, inhibits tumor growth and enhances anti-tumor immunity in mice by regulating PD-L1[79, 80].

When PD-1 binds to ligand, it inhibits T cell response and reduces T cell secretion of IFN-γ[61]. Studies have found that IFN-γ secreted by CD8⁺ T cells after tumor antigen recognition can upregulate PD-L1 expression. The subtype 2 protein
kinase D induced by IFN-γ is a vital factor regulating PD-L1. Inhibition of PKD2 activity can lead to down-regulation of PD-L1 expression and promote a strong anti-tumor immune response[61, 63, 68, 81]. Studies have indicated that IFN-γ induces upregulation of PD-L1 expression in cancer cells mainly through JAK-STAT pathway. By analyzing the data in TCGA, it is concluded that PD-L1 expression is positively correlated with IFN-γ characteristics[82, 83](Figure 5). In addition to cancer cells, PD-L1 also exists on the surface of its derived exosomes, and overexpression of IFN-γ or PD-L1 increased the level of PD-L1 in exosomes[84, 85]. Classical double-positive T(DPT) cells, known as naive T cells in the thymus, show strong immune response after stimulation, which improves the prognosis of HCC patients. The unique distribution of PD-1+ DPT in HCC verifies this conclusion[86].

Although PD-1 ligand PD-L1 has been studied deeply, the detailed mechanism of another PD-1 ligand PD-L2 is still unclear. Compared with PD-L1, PD-L2 has weaker immunosuppressive effect in animal models commonly used in tumor immunology research[70]. But the effect of low PD-L2 expression as a measure of immune infiltration is better than PD-L1. PD-L2 is superior to PD-L1 in evaluating anti-tumor immunity and IFN-γ signal transduction[87, 88]. A study shows that PD-L2 and other B7-28 family molecules can be used as prognostic indicators of immunotherapy. The activation of JAK-STAT pathway can up-regulate the expression of PD-L2, and blocking this activation can increase the production of IFN-γ[89]. Some studies have reported that PD-L2 positivity and overexpression are associated with adverse
prognosis in terms of OS for HCC[90].

3.1.2. CTLA-4 and CD80/CD86

CTLA-4 plays a negative regulatory role in the immune system, mainly expressed on Treg cells. The expression of CTLA-4 is up-regulated when T cells are activated, and the degree of T cell inflammatory response is reduced[91, 92]. TGF-β1 upregulates PD-1 and CTLA-4 expression through TGF-βR/CaN/NFATc1 signaling in a dose-dependent manner, thereby enhancing tumor immune escape in HCC[93]. CD28 and CTLA-4 are homologous glycoproteins of the immunoglobulin superfamily. Contrary to CTLA-4, the activation of CD28 signaling pathway by B7 leads to the production of T cell cytokines and the increase of T cell proliferation[94]. CTLA-4 mediates immunosuppression by competing with CD28 for B7 protein and disrupting CD28 signaling pathway. After binding to B7 protein, CTLA-4 inhibits the destruction of proximal TCR signaling and central supramolecular cluster (c-SMAC) in immune synapses. B7/BB1 is a cell surface protein called CD80, and B7-2 (CD86) is another CTLA-4 ligand (Figure 4). These ligands were highly expressed in antigen presenting cells (APC)[95, 96]. In addition, CTLA-4 reduces the expression of B7 molecules on APC by producing cytokines such as IL10 or TGF-β that inhibit B7 expression[97, 98] (Figure 6). CTLA-4 also acquires ligands by transendocytosis (TE) and APC to degrade them in recipient cells[98, 99]. However, Yang Y et al. reported that B-1a cells in adult mouse spleen can also express CTLA-4. They established CKO mouse model and elucidated that CTLA-4 inhibits B-1a cell
CTLA-4 targeted therapy for HCC faces two challenges: poor efficacy and adverse reactions. Therefore, safer and more effective CTLA-4 targeted therapy is needed in medicine to improve the benefit-risk situation. Kvarnhammar AM et al. discovered that ATOR-1015, a CTLA-4 x OX40 bispecific antibody, could activate T cells by blocking CTLA-4 and significantly enhance antitumor response. Interestingly, they also found that ATOR-1015 enhanced the anti-tumor response to anti-PD-1 treatment. So they thought ATOR-1015 could be used in combination with anti-PD-L1 in the future[101].

### 3.1.3 Other Immune checkpoints

In the related studies of HCC, only PD-1 and CTLA-4 were well understood. In recent years, many new immune checkpoints have emerged and have achieved research results in other cancer fields. Although there are few studies on HCC, it is likely to be used in combination with existing treatment regimens for HCC in the future.

**TNFSF/TNFRSF**

Most immune checkpoints inhibit immune cell activation, but tumor necrosis factor receptor superfamily (TNFRSF) as T cell costimulatory receptor promotes immune cell activation[102] (Figure 4). Previous studies have shown that TNFRSF members can be highly expressed by activated CD4+ and CD8+ effector T cells and
nonactivated Tregs, thereby promoting and inhibiting adaptive immunity, respectively[103, 104]. In effector T cells, the activation of TNFRs can promote the proliferation and differentiation of CD4+ and CD8+ lymphocytes, and also participate in the apoptosis of T cells[105]. Although the function of TNFRSF is poorly understood in Treg cells, these receptors release the necessary signaling molecules to maintain thymus development and proliferation[106]. It was found that after T cell activation in vitro, only the expression of GITR was up-regulated in TNFRSF members of Tregs, and the expression levels of TNFR2, 4-1BB or OX40 on resting Tregs were low. The agonists of TNFR2, 4-1BB, GITR, and DR3 need to activate classical NF-κB pathways to co-stimulatory Tregs. TNFRSF co-stimulation in Tregs is also conducive to the expression of IL-4, IL-5, IL-13 and IL23p19 immune molecules[107]. In recent years, more and more studies focus on OX40 and CD27, which are also members of TNFRSF. Clinical trials of agonists targeting OX40 and CD27 with tumors are under way, combination of OX40 and CD137 induces T cell proliferation in a short time, which may bring new directions for the treatment of HCC[108, 109]. The ligand of CD27 (TNFRSF7) is CD70, which affects innate immune system by increasing IFN-γ production by NK cells. Studies have found that CD27/CD70 signal transduction is very important for anti-cancer immunity, and the combination of agonistic CD27 antibodies and PD-1 blocking has the highest curative effect in solid tumor clinical trials[108]. Although there are few studies on CD27 and HCC, it has shown good anti-tumor effect on most solid tumors.
CD155/TIGIT

T cell immunoreceptor with immunoglobulin and ITIM domain (TIGIT) is a potential new target for cancer immunotherapy in addition to CTLA-4 and PD-1. It can effectively inhibit innate immunity and adaptive immunity[110, 111] (Figure 4). TIGIT is expressed on TILs of various human tumors, and its expression on TILs is closely related to PD-1 expression. TIGIT expression was detected in all tumor-derived PD1^{Hi} CD8^{+} T cells[76]. In addition, compared with TIM-3 and LAG-3, TIGIT is also expressed on CD8^{+} PD-1 int TIL of patients with high PD-1 expression. Compared with single PD-1 blocking, the combined blocking of TIGIT and PD-1 obviously enhances the proliferation of CD8^{+} TILs[112, 113]. TIGIT mainly has two ligands: CD155 (PVR) and CD112 (PVRL2, nectin-2), which have the highest affinity with CD155[110]. The expression of CD155 was significantly up-regulated in tumor cells of various cancers and correlated with poor prognosis[114]. TIGIT can produce immunosuppressive effect on CD8^{+} T cells of HCC through CD155/TIGIT signal transduction, such as PI3K, MAPK and NF-κB signaling pathways, reduce the contents of IFN-γ, tumor necrosis factor-α, and IL-17A, and increase the content of IL-10. It was found that the ratios of p-AKT/AKT and p-ERK/ERK in CD8^{+} T cells co-cultured with wild type HCC cells was significantly lower than that of CD155 knockdown cells, which was reversed by blocking TIGIT[115]. It can be speculated that CD155 overexpression in HCC cells may escape host immune response by upregulating TIGIT on TIL. According to this feature, Ge Z et al. studied the effect of TIGIT combined with PD-1 blocker on CD8^{+} T cells in hepatocellular carcinoma.
They found that combination of TIGIT and PD-1 significantly increased IFN-γ production by blocking enhanced CD8⁺ T cell function in vitro[112]. When regulating the functions of T cells and NK cells, it mediates signal transduction through interaction with costimulatory immune receptor CD226 (DNAM-1), inhibitory checkpoint receptor TIGIT and CD96, which is a very important immune ligand[116]. TIGIT can be detected on activated CD4⁺ T cells, CD8⁺ T cells and Foxp3⁺ Treg cells. TIGIT was highly expressed in CD4⁺ T cells and Treg cells in HCC patients. In addition, the expression of TIGIT was positively correlated with the expression of alpha fetoprotein (AFP)[117].

TIM-3 and Gal-9/PtdSer/HMGB1/CEACAM-1

TIM-3 is a kind of checkpoint receptor, recent studies have found that inhibition of TIM-3 enhances the anti-tumor effect of PD-1 blockers. TIM-3 was first discovered in 2002 and was initially thought to be a receptor expressed on IFN-γ-producing CD4⁺ and CD8⁺ T cells[75, 118]. Based on the TIM-3 expression, CD8⁺ T cells could be classified into three distinct subpopulations: PD1⁺, PD1⁻, and PD1⁻, but TIM-3 expression was only limited to PD1⁺ CD8⁺ T cells[119]. Through investigating the ability of CD8⁺ TILs to produce cytokines based on PD-1 expression and measuring cytokines, researchers observed that the frequency of IL-2-producing PD1⁺ CD8⁺ T cells was under-regulation, as well as IFN-γ and TNF-α, while the frequency of IL-10-producing was increased in PD1⁺ CD8⁺ T cells[76]. The characteristics of less cell metabolic activity and reduced production of pro-inflammatory cytokines suggest that
PD1hi CD8+ T cells are in T cell exhaustion [120].

TIM-3 has four ligands, including galactose lectin 9 (Gal-9), phosphatidylserine (PtdSer), high mobility group box-1 protein (HMGB1) and carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM-1) [75] (Figure 4). The combination of TIM-3 and Galectin-9 can mediate the apoptosis of effector T cells through the calcium-calpain-caspase-1 pathway and increase the production of IFN-γ in NKs [121-123]. PtdSer is a molecule exposed to apoptotic cells and binds to Tim-3 on DCs to mediate uptake and cross-presentation of apoptotic cells [124]. HMGB1 is mainly released by stressed or dying cells, responsible for transporting nucleic acids to internal vesicles, which is necessary to promote innate immune responses to pathogens and tumors. The binding of HMGB1 to TIM-3 interferes with this process, thereby weakening the antitumor effects of DNA vaccines and cytotoxic chemotherapy and inhibiting innate and antitumor immune responses [125]. The co-expression of TIM-3 and CEACAM1 was limited to a small fraction of activated T cells, and the function of TIM-3 is independent of CEACAM1. TIM-3 and CEACAM1 can promote inhibitory signaling pathways in T cells [126]. Tan S et al found that TIM-3 is the most abundant immune checkpoint receptor expressed on tumor NK cells in HCC. As an endogenous ligand, PtdSer induces Tim-3 phosphorylation and inhibits NK cell function by interfering with PI3K/Akt/mTOR pathway [22]. Cytokines in TME can induce the expression of TIM-3 in HCC cells, including IL-4, TGF-β and IL-6. Hepatocyte-Tim-3 receptor activates NF-κB phosphorylation, thereby stimulating IL-6 secretion and STAT3 phosphorylation [127].
This process promotes tumor growth and increases metastasis of HCC cells by enhancing epithelial-mesenchymal transition (EMT) [128]. It can be concluded that TIM-3 is not only expressed in immune cells, but also in HCC cells. These results show that TIM-3 may have other functions in addition to suppressing immune response. All studies further illustrated the important role of TIM-3 as a new participant in HCC progression and a promising target for HCC immunotherapy.

CD47/SIRPα

Under physiological conditions, CD47/SIRPα axis plays a protective role in preventing macrophages from clearing hematopoietic cells (Figure 4). However, under pathological conditions, cancer cells may use the axis to escape immune surveillance [129]. IL-6 secreted by TAMs upregulates CD47 expression in hepatocellular carcinoma cells, which inhibition of STAT3 signal destroys this effect. The results showed that there was a positive correlation between STAT3 phosphorylation and CD47 expression in tumor cells. Anti-phagocytosis mediated by CD47 may reduce the efficacy of TACE in hepatocellular carcinoma cells treated with chemotherapy drugs [130]. Du K et al. drew on the specific expression characteristics of Glypican-3 (GPC3) in HCC and the inhibitory effect of CD47 on macrophages to generate a novel bispecific antibody (BsAb): GPC3/CD47 BsAb. They demonstrated that GPC3/CD47 BsAb has potent antitumor activity against tumor cells expressing double antigens [131]. Du J et al. also designed a new anti-tumor therapy. They used the principle of CD47 surface functionalization (ExosCD47) to make exosomes
effectively avoid the phagocytosis of mononuclear phagocyte system (MPS) to construct exosomes, and encapsulated ferroptosis inducer (Erastin, Er) and photosensitizer (Rose Bengal, RB) into exosomes to induce iron death of HCC cells[132]. These provide antibody design information for the future development of innovative immunotherapy.

IDO/TDO

Tryptophan is an essential amino acid, which is metabolized mainly through the kynurenine pathway. Indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO or TDO2) are the starting enzymes and key enzymes to catalyze this pathway (Figure 4). It has been found that the removal of tryptophan in the microenvironment can inhibit the proliferation and activity of T cells. Kynurenine is an immunosuppressive molecule that inhibits the proliferation and activity of T cells and natural killer cells[133]. TDO promotes EMT through the Kyn-AhR pathway, contributing to the invasion and metastasis of HCC and leading to poor prognosis[134]. Chinnadurai R et al. found in the study that canine uridine inhibited T cell proliferation in the absence of PD-L1 Ig, and the inhibitory effect of the combination of the two on T cell proliferation was better than that of them alone. In addition, PD-L1 Ig and canine uridine synergistically inhibited IFN-γ secretion[135]. High expression of IDO in tumor cells can promote the expansion, recruitment and activation of MDSCs[136]. Clinical trials of IDO1 inhibitor BMS-986205 combined with Nivolumab as first-line or second-line therapy for HCC patients are underway.
(ClinicalTrials.gov Identifier: NCT03695250)[137, 138]. Therefore, canine uridine pathway and small molecule inhibitors of IDO are expected to become potential tumor immunotherapy drugs. However, the TME of HCC is extremely complex. In order to determine the immune regulation pathway and interaction between IDO and other ICI, it is necessary to further study the mechanism and function.

LAG-3/FGL1

Lymphocyte activating gene 3 (LAG-3) is an immunosuppressive receptor, and major histocompatibility complex II (MHC-II) is a typical ligand[139]. However, recent studies have shown that fibrinogen-like protein 1 (FGL1) is another major LAG-3 functional ligand (Figure 4). FGL1 is a protein secreted by hepatocytes, as a mitogen to promote hepatocyte proliferation. However, FGL1 is usually low in normal hepatocytes, while it is significantly increased in HCC cells. The final results support FGL1/LAG-3 pathway as a potential target for immune escape and cancer immunotherapy[140]. Galectin-3 and C-type lectin-like domain containing-4g (Clec4g) have been proved to interact with LAG-3 and inhibit T cell function, but the mechanism is not completely related to LAG-3[139, 141, 142]. The levels of LAG-3, FGL1, PD-L1 and CD8+ T cells in 143 HCC patients were evaluated by multiple immunofluorescence. It was found that the density of LAG-3+ cells was positively correlated with the level of FGL1 and the expression of PD-L1, but the correlation between LAG-3+ cells and the former was significantly stronger than that of the latter. In addition, the number of CD8+ T cells was positively correlated with PD-L1 level,
but negatively correlated with FGL1 expression[143]. Therefore, the expression of LAG-3 may represent a biomarker for unfavorable prognosis of HCC. Wang J et al. studied the therapeutic mechanism of Oxysophocapine on HCC. In this experiment, compared with anti-IL-6R treatment alone, Oxysophocarpine combined with anti-IL-6R did not show more effective inhibition on the expression of FGL1, P-JAK2 and P-STAT3, indicating that Oxysophocarpine inhibits IL-6-mediated JAK2/STAT3 signaling activation in HCC cells to downregulate FGL1 expression, thereby improving the anti-LAG-3 therapeutic effect[144].

3.2. ICI clinical trials in HCC

After sorafenib first-line treatment, the FDA has approved three other therapies, including nivolumab, pembrolizumab and nivolumab plus ipilimumab in HCC treatment[4].

Nivolumab--anti-PD-1 monoclonal antibody

A phase I/II study investigated the role of immunotherapeutic agent nivolumab in disease progression in patients with advanced HCC receiving at least one systemic treatment, including sorafenib, or intolerance to sorafenib[145]. Based on the findings, the FDA accelerated approval of nivolumab as a second-line treatment for advanced HCC in September 2017[146] (Table 1).

A randomized study showed a comparison between nivolumab (NIVO) and sorafenib (SOR) as first-line treatment in patients for aHCC[147]. A total of 743 patients with aHCC participated in this study. The shortest follow-up period was 22.8
months. The median survival time of patients after nivolumab treatment was longer
than that after sorafenib treatment (15.2 vs 13.4 months, HR 0.85 [95%CI: 0.72-1.02],
P=0.075). Although the predefined threshold of statistical significance was also not
met (HR 0.84, P=0.0419), NIVO showed better therapeutic effect than SOR in
patients with aHCC.

Choi WM et al. evaluated the clinical results of nivolumab in patients with
Child-Pugh B HCC through a real-world cohort study[148]. The study involved a total
of 203 patients, 132 with Child-Pugh A and 71 with Child-Pugh B. The longest
follow-up period was 37 months, with a median of 5.6 months. 146 patients died
during the follow-up period and 150 patients deteriorated after nivolumab treatment.
ORR in Child-Pugh B group was remarkably lower than that in Child-Pugh A group
(2.8 % vs 15.9 %), but disease control rate (DCR) was lower than that in Child-Pugh
A group (22.5 % vs 42.4 %). After statistics, researchers found that the OS of Child-
Pugh A group was longer than Child-Pugh B group. (42.9 vs. 11.3 weeks; 95%
confidence interval [CI], 2.15–4.24; p < 0.001), as well as median progression-free
survival (PFS) (7.4 vs. 6.0 weeks; 95% CI, 1.22–2.29; p = 0.014). In this study, most
HCC patients are caused by HBV infection, so the universality of this study may be
limited and more cases are needed to improve the results.

In the phase 2/3 trial CheckMate 040 Cohort 5 (NCT01658878), patients with
aHCC and Child-Pugh B cirrhosis received intravenous nivolumab 240 mg every 2
weeks in order to explore whether it is suitable for Child-Pugh B aHCC patients. The
results showed that ORR was 12% (95% CI 5-25%), disease control rate was 55%
(95% CI 40-69%), and median duration of response (DOR) was 9.9 months (95% CI 9.7-9.9). Thus, the investigators concluded that, nivolumab showed good therapeutic effect and safety for Child-Pugh B aHCC patients[149].

**Pembrolizumab--anti-PD-1 monoclonal antibody**

In 2018, pembrolizumab was approved by the FDA for patients with HCC previously treated with sorafenib[150]. It was evaluated a randomized, double-blind, phase III trial (KEYNOTE-240). A total of 413 subjects in this study were characterized by ineffective treatment of sorafenib. The patients were randomly divided into pembrolizumab group and control group according to the ratio of 2:1. The experimental group received intravenous injection of 200 mg pembrolizumab every 3 weeks while the control group received the same amount of saline placebo for at least 35 cycles. Median OS was 13.9 months (95% CI, 11.6-16.0 months) in the pembrolizumab group and 10.6 months (95% CI, 8.3-13.5 months) in the control group (HR, 0.781; 95% CI, 0.611-0.998; P = 0.0238). In addition, the median PFS of pembrolizumab group was slightly longer than that of placebo group (3.0 vs 2.8; 95% CI; 0.570-0.904; P = 0.0022). Although the median PFS of the two groups was close, the Kaplan-Meier curve showed that the efficacy of pembrolizumab was better in some patients after long-term use. The study did not meet its prespecified statistical dual end points of improving PFS and OS with pembrolizumab, but the results show that pembrolizumab has good therapeutic effect in patients.

A study aimed to evaluate the tolerance, safety and efficacy of lenvatinib plus
pembrolizumab in unresectable hepatocellular carcinoma (uHCC) has recently obtained experimental results (ClinicalTrials.gov identifier NCT03006926)[151]. In this Ib multicenter open label study of 100 patients, lenvatinib plus pembrolizumab yielded a definite response rate (46 % by mRECIST; 36 % by RECIST v1.1) per independent imaging review (IIR), median PFS of 9.3 months (by mRECIST; 8.6 months by RECIST v1.1) per IIR, and median OS of 22.0 months. This suggested that lenvatinib plus PD-1 inhibition and pembrolizumab monoclonal antibody lead to good antitumor effect. Preclinical data indicated that the immunoregulation of lenvatinib enhanced the activity of pembrolizumab monoclonal antibody, leading to increased tumor sensitivity.

**Ipilimumab—anti-CTLA-4 monoclonal antibody**

In phase 1/2 studies, PD-1 inhibitors have shown therapeutic efficacy as second-line therapies for HCC[145, 152]. The combination of nivolumab and ipilimumab has higher safety, expected objective response rate and sustained response. The checkmate 040 randomized clinical trial (ClinicalTrials.gov identifier NCT01658878)[153]. In this experiment, patients with advanced HCC who had previously received sorafenib treatment were randomly divided into three groups and treated with different schemes, and then the safety of different schemes was evaluated. Based on those results, one group of schemes (4 doses nivolumab 1 mg/kg plus ipilimumab 3 mg/kg every 3 weeks then nivolumab 240 mg every 2 weeks) get the best experimental results. The objective response rate of the group was 32% (95% CI, 20% to 47%). In the
experiment, the group did not meet the median (range) response duration (8.3 to 33.7+). Of the 49 patients involved in the study, 46 had any-grade treatment-related adverse events and one died of pneumonia of grade 5. Taken together, this treatment received accelerated approval in USA. Similar results were obtained in another study (ClinicalTrials.gov identifier NCT03222076)[154]. Researchers found that nivolumab plus ipilimumab could also be used during perioperative period for resectable HCC.

Although immune checkpoints have brought new development directions for HCC treatment, this treatment has many adverse reactions and poor efficacy. To explore the effective treatment for patients with advanced HCC who failed to block PD-1 pathway, Wong JSL et al. designed a combination therapy of CTLA-4 and PD-1 blockers, namely that all patients needed to receive ipilimumab 1 mg/kg with nivolumab 3 mg/kg or pembrolizumab 2 mg/kg scheduled every 3 weeks[155]. About half of patients had primary drug resistance. The median follow-up was 37.7 months (95% CI: 32.8 to 42.7). According to statistical analysis, ORR reached 16 % and approximately 40% of patients achieved clinical benefits in this experiment. The median DOR was 11.5 months (95% CI, 2.76 to 30.3). The median OS reached 10.9 months (95% CI, 3.99 to 17.8). These data provide a new research direction for solving the urgent clinical problems of anti-PD-1/L1 refractory advanced HCC patients.

3.3 Combination therapy related to ICIs in HCC

Adverse effect of ICIs
Use of ICIs is the most important breakthrough in cancer therapy in the past decade. ICIs, including anti-CTLA-4, anti-PD-1 and anti-PD-L1 antibodies, are increasingly being used in various malignancies, but a series of new immune-related adverse events (irAEs) follow. When irAEs are serious, it can even endanger life[156]. A study in the United States showed that the recurrence rate of the same irAEs was 28.8% when cancer patients were treated with the same ICI again[157]. This undoubtedly brings a series of new challenges in clinical treatment. It was found that compared with the single use of anti-CTLA-4 monotherapy, the use of anti-PD-1 or anti-PD-L1 monotherapy and combination therapy would lead to more severe irAEs. In the experiment of nivolumab combined with ipilimumab in patients with advanced HCC (ClinicalTrials.gov Identifier: NCT01658878), the results showed that the incidence of adverse reactions of nivolumab and ipilimumab regimen was higher than previously reported nivolumab monotherapy[153]. In addition, the recurrence rate of colitis was higher than those of other irAEs[157] (Table 2). Clinically, the adverse reactions of ICI include autoimmune endocrine diseases, colitis, pituitary inflammation, hepatitis, pneumonia, etc[158]. In an experiment on the clinical index of long-term survival of advanced hepatocellular carcinoma treated with immune checkpoint, the patients were divided into short-term survival group (31 patients) and long-term survival group (5 patients). Interestingly, two patients (40 %) in the long-term survival group had grade 3 or 4 immune-related adverse events (IrAEs-3/4), but no IrAEs-3/4 was found in the short-term survival group. So researchers believe that IrAEs-3/4 may be associated with long-term survival in patients with advanced
However, there are only five long-term survival groups in this study, and the sample is not representative. In-depth study of irAEs can deepen our understanding of autoimmune diseases and provide new ideas and clues for the treatment of autoimmune diseases.

3.4 Combination of VEGF or VEGFR inhibition and ICIs

Background and preclinical studies

HCC is a kind of highly vascularization tumor with abundant arterial blood flow. Patients with advanced HCC often have excessive blood vessels and obvious vascular abnormalities[160, 161]. Therefore, antiangiogenic drugs have good therapeutic prospects. All FDA approved systemic therapies for HCC are molecular targeted therapies that target VEGF signaling pathways leading to anti-angiogenesis[162]. HCC identified a new subtype, designated as macrotrabecular-massive HCC (MTM-HCC). It had frequent satellite nodules and macrovascular and/or microvascular infiltration, with high invasiveness. Angiogenesis activation is a significant feature of MTM-HCC, in which angiopoietin 2 and VEGF-A are overexpressed[163]. VEGF-A and pro-inflammatory cytokines induce endothelial cells to express FasL, thereby obtaining the ability to kill CD8+ T cells, but Treg cannot be killed. The pharmacological function of VEGF-A increases the number of CD8+ cells in tumor and inhibits tumor growth[160, 164]. Among the approved MKIs for the treatment of HCC, sorafenib’s immunoregulatory effect has been the most widely studied. A large number of studies have elucidated that sorafenib enhances anti-tumor immunity by
increasing the M1 polarization of TAMs, enhancing the infiltration and function of CD4+ and CD8+ T cells, inhibiting the number of Tregs and reversing the function of MDSCs in tumor microenvironment[165]. In addition, regorafenib induced polarization of M1 macrophages to promote the proliferation and activation of CD8+ T cells[166, 167].

Although immune checkpoint blockers have been approved by FDA for HCC treatment, the use of PD-1 blockers is only beneficial for a small fraction of patients with hepatocellular carcinoma. Similarly, combined VEGF or VEGFR inhibition and ICI in patients with HCC can also have a good therapeutic effect[168, 169]. The mouse model of HCC was established and the results showed that the growth of primary tumor was significantly delayed by specific blocking of vascular endothelial receptor 2 by mouse antibody, but the survival time did not change obviously. However, after dual anti-PD-1/VEGFR-2 treatment, the growth of primary tumors was inhibited, and the survival rate was estimated to be twice as high as the original. After further investigation of the mechanism, researchers found that the upregulation of PD-L1 in HCC depends on VEGFR-2 blocking in endothelial cells, which is mediated by IFN-γ expression in endothelial cells[168]. A new study shows that anti-PD-1 treatment with levatinib enhances anti-tumor immune response in HCC by activating immune pathways, reducing Tregs infiltration and inhibiting TGF-β signaling[170].

Clinical studies
The network meta-analysis (NMA) of 14 low-bias risk trials showed that the combination of atezolizumab and bevacizumab had the best clinical efficacy in the first-line treatment of advanced HCC patients[171]. A therapeutic strategy of unresectable HCC had previously been studied using the combination of atezolizumab with bevacizumab (a kind of VEGF inhibition), which also showed encouraging antitumor activity and safety[172]. The IMbrave150 (ClinicalTrials.gov identifier NCT03434379) trial compared 1200 mg of atezolizumab plus 15 mg/kg of bevacizumab intravenously every 3 weeks, 400 mg of sorafenib orally twice daily. Statistical analysis showed that the overall survival of patients in atezolizumab-bevacizumab group was significantly longer than that in sorafenib group. The 6-month and 12-month survival rates of the atezolizumab–bevacizumab group were 84.8 % (95%CI, 80.9-88.7) and 67.2 % (95 % CI, 61.3-73.1), respectively. The 6-month and 12-month survival rates of sorafenib group were 72.2 % (95%CI, 65.1-79.4) and 54.6 % (95 % CI, 45.2-64.0), respectively. In addition, progressive survival in atezolizumab-bevacizumab was also markedly longer than in sorafenib (median, 6.8 months [95% CI, 5.7-8.3] vs. 4.3 months [95% CI, 4.0-5.6]).

Several other trials are assessing the clinical efficacy of VEGFR blockers combined with ICI. The efficacy and safety of camrelizumab (an anti-PD-1 monoclonal antibody) plus apatinib (a vascular endothelial growth factor [VEGFR]-2 tyrosine kinase inhibitor) were evaluated in patients with aHCC[173]. Oral apatinib 250 mg was given daily. At the same time, patients received intravenous injection of camrelizumab 200 mg (weight ≥ 50 kg) or 3 mg/kg (weight < 50 kg) every 2 weeks.
Of a total of 190 patients, 70 received first-line setting and 120 received second-line setting. According to the cohorts, the median PFS was 5.7 months (95% CI, 5.4-7.4) and 5.5 months (95% CI, 3.7-5.6), respectively. Although the median OS was considered immature, after estimating the survival curve by Kaplan-Meier analysis, the 12-month survival rates were 74.7% (95% CI, 62.5-83.5) and 68.2% (95% CI, 59.0-75.7), for the first-line and second-line cohorts. ORR was 34.3% (24/70; 95% CI, 23.3-46.6) in the first-line and 22.5% (27/120; 95% CI, 15.4-31.0) in the second-line cohort. The trial showed that combination of camrelizumab and apatinib achieved potent efficacy in aHCC both in the first-line and second-line settings.

4. Localized treatments in HCC

**Neoadjuvant and adjuvant therapy**

The purpose of adjuvant therapy is to help reduce the postoperative recurrence rate of HCC patients. Neoadjuvant therapy can significantly reduce the tumor and inhibit the proliferation and metastasis of tumor cells, so as to improve the clinical symptoms of patients and better accept surgical treatment[174, 175]. However, the role of neoadjuvant therapy in the treatment of HCC is still unclear. In fact, there are relatively few studies on the concept of neoadjuvant therapy for HCC[174]. In the data we found, neoadjuvant therapy and adjuvant therapy do not appear to be required by the guidelines for the treatment of HCC and there are no FDA approved treatment options for adjuvant or neoadjuvant HCC therapy after resection/ablation with curative intent. The United States Cancer Board defines neoadjuvant therapy as
radiotherapy (RT) and systemic therapy[176]. Both methods include TACE, radiotherapy and ICIs. In addition, adjuvant therapy included IFN-α, molecular targeted drugs, traditional Chinese medicine, and new adjuvant therapy included systemic therapy, anti-viral therapy, HAIC, transarterial radioembolization (TARE). Although TACE is primarily applied to neoadjuvant therapy, it is also assessed as an adjuvant therapy after resection. The study found that preoperative RT can be used as a bridging therapy in patients with advanced HCC, and adjuvant RT may be superior to TACE in terms of recurrence-free survival (RFS) and OS. ICIs have been approved for adjuvant therapy for other solid tumors, and ICIs may also play a role as a new adjuvant therapy during perioperative period of HCC. In preclinical studies, IFN-α was discovered to reduce the occurrence of tumor recurrence after orthotopic liver transplantation. TKIs have achieved great success in many kinds of solid tumors including HCC. Sorafenib is the first approved TKI for advanced HCC. In a study of sorafenib as adjuvant therapy for HCC, the recurrence rate of patients after hepatectomy treated with sorafenib was significantly lower than that of the control group[177]. Traditional Chinese medicine has a long history in China. Huaier granules are widely used in the treatment of various cancers, and have been proved to be able to prolong RFS of HCC patients as adjuvant therapy[178]. Systemic therapy, including systemic chemotherapy, drug therapy and immunotherapy, can be used as a new adjuvant therapy to reduce HCC staging[174, 175, 179]. In HCC, hepatic artery is the main blood source conducive to tumor growth, so HAIC selectively delivers chemotherapy agents in the liver parenchyma through catheters or pumps to directly
attack local diseases[180]. TARE is the use of radioactive elements produced by the way of intra-arterial injection of liver cancer radiotherapy, more suitable for HCC patients with portal vein tumor thrombosis.

After considering the established role of PD-1 and CTLA-4 blockers in adjuvant therapy for melanoma patients, especially ipilimumab and pembrolizumab have been approved for melanoma, researchers wondered whether ICI could play a role in neoadjuvant therapy or adjuvant therapy for HCC patients[181-183]. Nivolumab and pembrolizumab have been studied as adjuvant therapy for HCC (NCT03383458 and NCT03867084). Currently, many ongoing phase 3 clinical trials for adjuvant therapies evaluate an anti-PD-1 antibody with or without an anti-angiogenic agent, such as adjuvant pembrolizumab (KEYNOTE-937, NCT03867084)[184], adjuvant nivolumab (CheckMate 9DX, NCT03383458)[185], adjuvant durvalumab (anti-PD-L1 antibody) with or without bevacizumab (angiogenesis inhibitor) (EMERALD-2, NCT03847428)[186], adjuvant toripalimab (JS001) (JUPITER 04, NCT03859128)[187] and adjuvant atezolizumab plus bevacizumab (IMbrave050, NCT04102098)[188].

Locoregional therapies

HCC usually occurs in chronic inflammatory environments, especially inflammation caused by viral hepatitis. Liver transplantation and surgical resection are the main treatments for patients with early HCC[189]. However, when a large number of patients are diagnosed, the disease is already in the middle and late stages or
serious complications, which undoubtedly increases the risk of surgery, so it is not suitable for surgical treatment[189]. Local treatment has become a new choice for these patients, mainly including transarterial embolization (TAE), TACE, TARE, and ablative therapies[190, 191]. Studies have verified that direct killing of tumors can lead to activation of the immune system. However, in recent years, TAE and TARE are rarely used in combination with ICI in HCC-related research. Leuchte K et al. tested the effect of microwave ablation on tumor specific immune response in patients with HCC[192]. The researchers analyzed specific phenotypes of T and B cell subsets in 23 patients treated with MWA alone. The results demonstrate that after MWA treatment, most T and B cell subsets did not change significantly, and the frequency of effector memory T cells decreased (23.7% ± 1.6, day 0 28.5% ± 2.3; p < 0.01), while plasma mother cells increased on the 7th day after treatment (8.3% ± 1.7, day 0 4.0% ± 1.2; p = 0.02). They also analyzed whether the specific changes of circulating immune cell subsets in patients with early recurrence and long-term remission were related to MWA. The data revealed that compared with patients with long-term remission, CD69+ T cells were enriched in patients with recurrence. T cell depletion marker PD-1 and Tim-3 mediated NK cell tolerance were also upregulated in patients with early recurrence. These results suggested that 30% of patients had increased specific immune response, that is, these patients showed increased TAA-specific IFN-γ or IL-5 secretion after stimulation with HCC-related antigens after MWA. This experiment highlighted the immunogenicity of MWA and was important for detecting immune response and inhibiting anti-tumor immunity in ongoing and future clinical
trials of MWA combined with ICIs.

TACE is not a radical treatment, which may lead to poor results such as deterioration of liver function and extrahepatic metastasis[193, 194]. Koroki K et al. studied and evaluated the therapeutic effect of TCAE in patients with medium-term HCC[193]. Studies had shown that the results of TACE in patients with medium-term HCC were closely related to the number and size of tumors. TACE-induced hypoxia promotes the release of proangiogenic cytokines and the death of immunogenic cells, and promotes tumor angiogenesis and regulates the function of immune cells in tumor microenvironment[195]. Therefore, the combination therapy of TACE and sorafenib plus ICIs may have promising therapeutic effect and safety in advanced TACE refractory HCC.

A recent review of the efficacy and safety of TACE combined with sorafenib plus immune checkpoint inhibitors in the treatment of advanced TACE refractory HCC[196]. Compared with the TACE + Sor group, the OS and median PFS TACE + Sor + ICIs group were significantly prolonged, and the survival rate of patients was significantly improved. Furthermore, the median PFS of patients receiving nivolumab was similar to that of patients receiving pembrolizumab [13.6 months (95 % CI, 12.02-15.18) vs. 13.2 months (95 % CI, 6.85-19.55, z = 0.32, P = 0.859)], and as well as the median OS [20.0 months (95% CI, 12.92-27.08) vs. 25.6 months (95% CI, 13.53-37.67, z = 0.05, P = 0.820]. The study demonstrated that TACE combined with sorafenib plus ICIs was effective in patients with advanced refractory HCC.
5. Future and Conclusions

ICI has made great progress in the treatment of solid tumors in the past decades, bringing hope for cure of patients. Although the response rate of ICI in HCC patients is not high at present, with the improvement of our understanding of the interaction between ICI and adaptability and innate immune response, more new treatment modes will emerge. Most of the current immunotherapy strategies are to combine ICI with other immune-targeted strategies. And the combination of anti-PD-1+anti-CTLA-4 (nivolumab+ipilimumab) has received FDA’s accelerated approval[197]. Other immune checkpoints, such as TNFRSF, LAG-3, TIM-3, TIGIT, can regulate T cell function and play an important role in tumor immune escape[91]. The anti-tumor effect of ICIs targeting LAG-3, TIM-3 or TIGIT in humans is currently under study. Early trials of combination therapy of anti-TIM-3 and anti-TIGIT antibodies with PD-1 or CTLA-4 in a variety of tumor types are also ongoing and need further exploration[113].

In recent years, platinum-based chemotherapy combined with PD-1/PD-L1 inhibitors has shown efficacy in a variety of cancers, which has gradually become the focus of attention. Studies have found that there are two main therapeutic mechanisms for platinum-based chemotherapy combined with PD-1/PD-L1 inhibitors. Firstly, platinum chemotherapy has a positive effect on immune regulation, which can increase the sensitivity of tumor cells to PD-1/PD-L1 inhibitors[198]. On the other hand, higher doses of platinum may increase the expression of PD-L1 in tumor cells but decrease the activity of T cells[198, 199]. Strategically combining ICIs with other
treatment methods and utilizing their potential synergistic can maximize the clinical activity of combined therapy and establish a lasting immune response, which is crucial to the development of new therapies for cancer.

With the progress of ICI, we are entering a new era of HCC immunotherapy. Immunocytes in HCC tumor immune microenvironment provide new targets and signaling pathways for immunotherapy. These new therapies alleviate the condition of HCC patients and prolong their survival time. Although ICIs still have many disadvantages, such as low response rate, more side effects and complications, many treatments combining ICIs with other therapies (including VEGF or VEGFR inhibition, neoadjuvant and adjuvant therapy, locoregional therapies) have been developed in recent years. Therefore, improving understanding of cancer immunology and how to lead to immune tolerance in HCC is critical to translating findings into clinical outcomes, avoiding unnecessary medications and guiding rational treatment.

Abbreviations

APC: antigen presenting cells; AFP: alpha fetoprotein; aHCC: advanced hepatocellular carcinoma; BCLC: Barcelona Clinic HCC; BsAb: bispecific antibody; CEACAM-1: carcinoembryonic antigen-related cell adhesion molecule 1; C/EBPβ: CCAAT-Enhancer-Binding Protein Beta; Clec4g: C-type lectin-like domain containing-4g; c-SMAC: central supramolecular cluster; CTLA-4: cytotoxic T lymphocyte 4; CTLs: cytotoxic T lymphocytes; DC: dendritic cells; DCR: disease control rate; DOR: duration of response; DPT: double - positive T; DRR: durable response rate; EMT: epithelial-mesenchymal transition; ERAD: endoplasmic
reticulum-associated degradation; FGL1: fibrinogen-like protein 1; Gal-9: galactose lectin 9; GPC3: Glypican-3; HAIC: hepatic arterial infusion chemotherapy; HAT: hepatic artery infusion pump; HCC: Hepatocellular carcinoma; HMGB1: high mobility group box-1 protein; HR: hepatic resection; HSC: hepatic stellate cells; ICIs: immune checkpoint inhibitors; IDO: 2,3-dioxygenase; Ig: immunoglobulin; IIR: independent imaging review; iNOS: inducible nitric oxide synthase; irAEs: immune-related adverse events; IrAEs-3/4: grade 3 or 4 immune-related adverse events; iTregs: induced-to-adjust T cells; KCs: Kupffer cells; LAG-3: Lymphocyte activating gene 3; MDSCs: myeloid-derived suppressor cells; M-MDSC: mononuclear MDSC; MPS: mononuclear phagocyte system; MHC-II: major histocompatibility complex II; MTM-HCC: macrotrabecular-massive HCC; NIVO: nivolumab; NK cells: natural killer cells; NMA: network meta-analysis; nTregs: natural regulatory T cells; OTUB1: OTU domain-containing ubiquitin aldehyde-binding protein 1; ORR: Objective Response Rate; PD-1: programmed cell death protein 1; PD-L1: programmed cell death ligand 1; PFS: progression-free survival; PMN-MDSC: polymorphonuclear MDSC; PtdSer: phosphatidylserine; RFS: recurrence-free survival; ROS: reactive oxygen species; RT: radiotherapy; SOR: sorafenib; TAA: tumor associated antigens; TACE: transarterial chemoembolization; TAE: transarterial embolization; TAMs: tumor-associated macrophages; TARE: transarterial radioembolization; TCR: T cell receptor; TDO or TDO2: tryptophan 2,3-dioxygenase; TGF-β: transforming growth factor-β; TE: transendocytosis; Th cell: T helper cell; TIGIT: T cell immunoreceptor with immunoglobulin and ITIM domain; TIL: tumor-infiltrating lymphocytes; TIM-3:
T cell immunoglobulin and mucin domain-containing protein 3; TKIs: Tyrosine kinase inhibitors; TME: tumor microenvironment; TNFRSF: tumor necrosis factor receptor superfamily; Tregs: regulatory T cells; uHCC: unresectable hepatocellular carcinoma; VEGF: Vascular endothelial-derived growth factor.

**Ethics approval and consent to participate**

Not applicable.

**Consent for publication**

Not applicable.

**Availability of data and materials**

All data generated or analyzed during this study are included in this article.

**Competing interests**

The authors declare that they have no competing interests.

**Funding**

This study was supported by the National Natural Science Foundation of China (81602575, 81701847, 61572200), Natural Science Foundation of Hunan Province (2017JJ3430, 2017JJ3497), Xiang Jiang Scholars Program/Hong Kong Scholars Program (XJ2016054).
Authors’ contributions

LZ designed the study. HJ and LZ drafted the manuscript. HJ, SQ, JH, JX, QL, YM and LZ collected the data and conducted the picture processing. LZ and YM revised the manuscript. All authors have read and approved the final version of manuscript.

Acknowledgements

Not applicable.

References


47.


48


targeting GPC3 and CD47 induced enhanced antitumor efficacy against dual antigen-expressing HCC.


146. De Mattia E, Cecchin E, Guardascione M, Foltran L, Di Raimo T, Angelini F, D'Andrea M and Toffoli...


54

10.1002/hep.32023
1425
1426
Junior PLS, Mahipal A, Ma WW, Jin Z, Mody K, Starr J, Borad MJ, Ahn DH, Murad MH and Bekaii-Saab T
1427
(2020) Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma: A Systematic
1428
1429
172. Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, Li D,
1430
1431
Investigators IM (2020) Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N
1432
1433
1434
1435
Wang S and Wang Q (2021) Camrelizumab in Combination with Apatinib in Patients with Advanced
1436
Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial. Clin Cancer Res
1437
27:1003-1011. doi: 10.1158/1078-0432.CCR-20-2571
1438
1439
1440
1441
1442
1443
1444
1445
177. Wang SN, Chuang SC and Lee KT (2014) Efficacy of sorafenib as adjuvant therapy to prevent early
1446
1447
doi: 10.1111/hepr.12159
1448
178. Chen Q, Shu C, Laurence AD, Chen Y, Peng BG, Zhen ZJ, Cai JQ, Ding YT, Li LQ, Zhang YB, Zheng
1449
1450
 LX, Mu Y, Zhang L, Zhang QS, Jiang B, Qian LX, Wang YJ, Liu JF, Qin XH, Li Q, Yin P, Zhang ZW and Chen
1451
XP (2018) Effect of Huaier granule on recurrence after curative resection of HCC: a multicentre,
1452
1453
179. Zhu XD, Li KS and Sun HC (2020) Adjuvant therapies after curative treatments for hepatocellular
1454
1455
1456
Arterial Infusion of Chemotherapy for Advanced Hepatobiliary Cancers: State of the Art. Cancers
1457
(Basel) 13. doi: 10.3390/cancers13123091
1458
1459
Groh JJ, Chiarión-Sileni V, Marquez-Rodas I, Butler MO, Maio M, Middleton MR, de la Cruz-Merino L,
1460
Arenberger P, Atkinson V, Hill A, Fecher LA, Millward M, Khushalani NI, Queirolo P, Lobo M, de Pril V,
1461
1462
and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind,
1463
1464
1465
Eroglu Z, Koon HB, Lawrence DP, Kendra KL, Minor DR, Lee CB, Albertini MR, Flaherty LE, Petrella TM,
1466
Streicher H, Sondak VK and Kirkwood JM (2020) Phase III Study of Adjuvant Ipilimumab (3 or 10


Wright K (2020) FDA Approves Nivolumab Plus Ipilimumab for the Treatment of Advanced HCC. Oncology (Williston Park) 34.


Figure 1. Interaction and functions of immune cells in HCC tumor microenvironment.

MDSC can secrete TGF-β, IL-10 and recruit Treg by expressing CD40. TAM can produce chemokines CCL22 and CCL17, and recruit Treg to transfer to cancer sites. IL-10 secreted by Treg promotes M2 polarization of TAM. DC promotes Treg by reducing IL-12 secretion. The number of NK cells in tumor tissues of HCC patients decreased, and the levels of IFN-γ and TNF-α secreted by NK cells decreased, but NK cells increased the expression of TIM-3. After blocking TIM-3, the function of depleted NK cells recovered rapidly.
Figure 2. Macrophages have two polarization directions. IFN-γ promotes M1 macrophage polarization by activating STAT1. IL-4 and IL-13 promote M2 macrophage polarization by activating STAT6. M1 and M2 macrophages have different functions in the liver.
Figure 3. M2 macrophage polarization related pathways. IL-4 activates Wnt/β-catenin signaling pathway in macrophages, resulting in up-regulation of c-Myc expression. C-Myc can promote M2 polarization. Long non-coding RNA LINC00662 up-regulated the expression of Wnt-3a by binding to miR-15a/16/107, activated Wnt/β-catenin signal, and promoted the proliferation and growth of liver cancer cells in vivo. Meanwhile, WNT3a induces M2 macrophage polarization by paracrine.
Figure 4. ICIs observed in immunocyte. Below are inhibitory receptors expressed on the surface of immune cells. The ligands of these receptors expressed by tumor cells lie above the image. IDO and TDO are enzymes in immune cells that react with L-tryptophan. Inhibitory receptor-ligand interactions leading to immune escape of cancer cells are called checkpoint inhibition.
Figure 5. CD8 + T cells upregulate PD-L1 expression in tumor cells. CD8 + T cells secrete IFN-γ after recognizing tumor antigens, bind to the corresponding receptors on tumor cells, and up-regulate the expression of PD-L1 through JAK-STAT pathway.
Figure 6. CTLA-4 and CD28 compete to bind to B7 protein (CD80/CD86). CTLA-4 promotes Treg to produce cytokines that inhibit B7 expression, such as IL-10 or TGF-β, and reduces the expression of B7 molecules on APC.
Table 1: The clinical trials on immune checkpoints and other therapeutic targets for HCC in recent years

<table>
<thead>
<tr>
<th>ClinicalTrials.gov Identifier</th>
<th>Trial name</th>
<th>Agent</th>
<th>Target</th>
<th>Endpoints</th>
<th>Phase</th>
<th>Actual Enrollment</th>
<th>Recruitment Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT03695250</td>
<td>CheckMate040</td>
<td>BMS-986205 vs Nivolumab</td>
<td>IDO1, PD-1</td>
<td>Safety/Tolerability/ORR</td>
<td>1/2</td>
<td>8</td>
<td>Active, not recruiting</td>
</tr>
<tr>
<td>NCT01658878</td>
<td></td>
<td>Nivolumab plus Cabozantinib +/− Ipilimumab</td>
<td>PD-1, CTLA-4, TKI</td>
<td>Safety/Tolerability/ORR</td>
<td>1/2</td>
<td>659</td>
<td>Active, not recruiting</td>
</tr>
<tr>
<td>NCT03006926</td>
<td></td>
<td>Pembrolizumab plus Lenvatinib</td>
<td>PD-1, TKI</td>
<td>Safety</td>
<td>1</td>
<td>104</td>
<td>Active, not recruiting</td>
</tr>
<tr>
<td>NCT03222076</td>
<td></td>
<td>Nivolumab +/− Ipilimumab</td>
<td>PD-1, CTLA-4</td>
<td>Safety/Tolerability</td>
<td>2</td>
<td>30</td>
<td>Active, not recruiting</td>
</tr>
<tr>
<td>NCT03434379</td>
<td>IMbrave150</td>
<td>Atezolizumab plus Bevacizumab vs Sorafenib</td>
<td>PD-L1, VEGFR, TKI</td>
<td>PFS/OS</td>
<td>3</td>
<td>558</td>
<td>Active, not recruiting</td>
</tr>
<tr>
<td>NCT03383458</td>
<td>CheckMate 9DX</td>
<td>Nivolumab</td>
<td>PD-1</td>
<td>RFS</td>
<td>3</td>
<td>545</td>
<td>Active, not recruiting</td>
</tr>
<tr>
<td>NCT03867084</td>
<td>KEYNOTE-937</td>
<td>Pembrolizumab</td>
<td>PD-1</td>
<td>RFS/OS</td>
<td>3</td>
<td>950</td>
<td>Recruiting</td>
</tr>
<tr>
<td>NCT03847428</td>
<td>EMERALD-2</td>
<td>Durvalumab +/− Bevacizumab</td>
<td>PD-L1, VEGFR</td>
<td>RFS</td>
<td>3</td>
<td>888</td>
<td>Recruiting</td>
</tr>
<tr>
<td>NCT03859128</td>
<td>JUPITER 04</td>
<td>Toripalimab</td>
<td>PD-1</td>
<td>RFS</td>
<td>2/3</td>
<td>402</td>
<td>Active, not recruiting</td>
</tr>
<tr>
<td>NCT04102098</td>
<td>IMbrave050</td>
<td>Atezolizumab plus Bevacizumab</td>
<td>PD-L1, VEGFR</td>
<td>RFS</td>
<td>3</td>
<td>668</td>
<td>Active, not recruiting</td>
</tr>
</tbody>
</table>
Table 2: Comparison between rechallenge and nonrechallenge cases after an irAE with at least 1 immune checkpoint inhibitor (n = 24 079)

<table>
<thead>
<tr>
<th>Initial irAE</th>
<th>No. (%)</th>
<th>Rechallenge after irAE (n = 6123)</th>
<th>No rechallenge after irAE (n = 17 956)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ICI</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anti–PD-1 or anti–PD-L1 alone</td>
<td>4360 (71.2)</td>
<td>12 321 (68.6)</td>
<td></td>
</tr>
<tr>
<td>Anti–CTLA-4 alone</td>
<td>791 (12.9)</td>
<td>3290 (18.3)</td>
<td></td>
</tr>
<tr>
<td>Combination therapy</td>
<td>972 (15.9)</td>
<td>2345 (13.1)</td>
<td></td>
</tr>
<tr>
<td>Type of initial irAE (Only five diseases with the highest rechallenge rate were selected)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Colitis</td>
<td>1745 (28.5)</td>
<td>5353 (29.8)</td>
<td></td>
</tr>
<tr>
<td>Pneumonitis</td>
<td>1288 (21.0)</td>
<td>4001 (22.3)</td>
<td></td>
</tr>
<tr>
<td>Thyroiditis</td>
<td>779 (12.7)</td>
<td>1977 (11.0)</td>
<td></td>
</tr>
<tr>
<td>Arthritis</td>
<td>491 (8.0)</td>
<td>1372 (7.6)</td>
<td></td>
</tr>
<tr>
<td>Hepatitis</td>
<td>473 (7.7)</td>
<td>1444 (8.0)</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: CTLA-4, cytotoxic T-lymphocyte antigen-4; ICI, immune checkpoint inhibitor; irAE, immune-related adverse event; PD-1, programmed cell death 1; PD-L1, programmed cell death 1 ligand 1.